Skip to main content

Table 1 Characteristics of the clinical trials included in the meta-analysis

From: Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

First Author [Reference No.]

Country

Enrolment period

Study*

Analysis

No. of patients

Age, years, mean

Gender,% male

Peg-IFN

Peg-IFN

Peg-IFN

α-2a/α-2b

α-2a/α-2b

α-2a/α-2b

Yenice [16]

Turkey

No information

RCT, unblinded

Per protocol

37/37

48.2 and 50.9^

35.1/27

50.8 and 50.85§

Di Bisceglie [17]

USA

No information

RCT, unblinded

Intention-to-treat

189/191

46.9/48.4

64/71

Escudero [18]

Spain

May 2001 to December 2006

Controlled

Intention-to-treat

59/58

45.8/45.1

66.1/60.3

McHutchison [19]

USA

March 2004 to June 2006

RCT#

Intention-to-treat

1,035/1,019

47.6/47.5

59.2/60.2

Ascione [20]

Italy

March 2004 to December 2006

RCT, unblinded

Intention-to-treat

93/93

51.3/48.9°

50.6/58.8°

Lee [21]

Korea

May 2004 to February 2009

Controlled

Intention-to-treat

21/16

53.4/53.6°

64.6/55.3°

Rumi [22]

Italy

September 2003 to June 2007

RCT, unblinded

Intention-to-treat

91/87

51.6/52.8°

60.4/54.8

  1. * RCT randomized controlled trial; # Random double-blinded with regard to the dose of Peg-IFN alfa-2b; ^ Male; § Female; ° All genotypes.